ETF Trends
07 Jul 2026, 21:04 UTC · 10w ago
Verdict
Headline leans bearish. We score LLY +0.90 across five claims.
Score contradicts the headline.
Leans bearish
From its wording — no explicit rating
+0.90strongly bullish
What the story claims
5 claims · scored −1 bearish … +1 bullish
Eli Lilly is developing next-generation weight loss treatments that have shown greater weight loss in clinical trials than earlier therapies.
More positive than 91% of claims this week
Viking Therapeutics' Phase 2 results for its dual GLP-1/GIP drug (14.7% weight loss in 13 weeks) have positioned the company as a popular takeover candidate.
Continue reading
5 related stories
More positive than 95% of ticker scores this week
Scored by the NIS engine · methodology.
Top 3 movers · tap to explore
More positive than 84% of claims this week
AbbVie is diversifying the obesity market with an amylin drug (ABBV-295) that showed nearly 10% weight loss after 12 weeks in Phase 1 trials.
More positive than 76% of claims this week
Scholar Rock and Regeneron are developing treatments specifically to preserve lean muscle mass lost during GLP-1 drug use.
More positive than 65% of claims this week
Hims & Hers Health is gaining market share by providing access to compounded GLP-1 medications as insurers reduce coverage for branded drugs.
More positive than 54% of claims this week
Which stocks this story touches
More positive than 95% of ticker scores this week
Strong growth in weight loss market with clinical trials showing high efficacy and expanded manufacturing.
More positive than 87% of ticker scores this week
Remains the largest holding in the weight loss ETF with a growing pipeline for obesity-related diseases.
More positive than 87% of ticker scores this week
Positive Phase 2 results for its weight loss drug have made it a popular takeover candidate.
More positive than 81% of ticker scores this week
Expanding its obesity pipeline and recently increased its allocation in the THNR index.
More positive than 81% of ticker scores this week
Expanding into the obesity market with promising early Phase 1 data for its amylin drug.
More positive than 81% of ticker scores this week
Developing a treatment to preserve lean muscle, addressing a key side effect of GLP-1 drugs.
More positive than 75% of ticker scores this week
Applying innovative RNA interference therapy to target fat storage pathways.
More positive than 75% of ticker scores this week
Gaining market share by offering compounded GLP-1 medications via its telehealth platform.
More positive than 75% of ticker scores this week
Focusing on the critical need to preserve skeletal muscle during weight loss.
More positive than 75% of ticker scores this week
Developing a dual-receptor drug in partnership with Eli Lilly for the obesity market.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Seeking Alpha
14h ago
More positive than 56% of relationship scores this week
[mutual] Innovent Biologics is developing a drug with Eli Lilly that targets GLP-1 and glucagon receptors.
−7.9%
Price is moving against the score
$1138.21 vs $1235.56 close before publication (Jul 7) · not market-adjusted
LLY chart →
